Denosumab Increasingly Used in Myeloma Despite High Cost Denosumab Increasingly Used in Myeloma Despite High Cost

Denosumab has captured 40% of the market share in just over a year despite a lack of superiority with zoledronic acid and a much higher price tag.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news